Successful analysis of effective mechanism for selection of therapeutic drug candidates in research on new coronavirus infection (COVID-19) using FRONTEO and AI

Home » corporate » News » 2020 » Successful analysis of effective mechanism for selection of therapeutic drug candidates in research on new coronavirus infection (COVID-19) using FRONTEO and AI
2020.04.24 Press release

--To the press -

Successful analysis of effective mechanism for selection of therapeutic drug candidates in research on new coronavirus infection (COVID-19) using FRONTEO and AI

 FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) uses the AI ​​system "Cascade Eye" that visualizes important genes and molecules related to diseases, which was originally developed. We are pleased to announce that we have succeeded in constructing a pathway map (connecting relationships such as genes) for the new coronavirus infection (COVID-19).

 

 We have succeeded in constructing a pathway map for the new coronavirus infection (COVID-19) using our drug discovery support AI system "Cascade Eye", and have successfully identified important molecules and genes related to the infection. I was able to clarify.By analyzing the papers on the molecules and genes shown on these maps, it is possible to search for candidates for existing drugs, and the molecules that are the targets of existing drugs are also known as shown in the figure below. FRONTEO will make this pathway map widely available to pharmaceutical companies and public institutions so that it can be used to select therapeutic agents.

 

Pathway map of the new coronavirus infection (COVID-19).Blue represents the causative gene, green represents the responsive gene, and beige represents the molecule that connects them.The genes and molecules shown in red are targets for existing drugs and tool compounds.

 

An enlarged version of the pathway map.Taking the central ellipse "TOP1" as an example, there are existing drugs such as irinotecan, edtecalin (both anti-malignant tumor drugs), lucanton (anti-microbial drug), and camptothecin (anti-cancer drug).

 

 "Cascade Eye" is judged by AI without human assumptions and biases, so in addition to discovering new targets and biomarkers that may be overlooked only by existing knowledge and experience, it is also useful for predicting efficacy and safety. Can also be applied with completeness.

 Even after the end of COVID-19, the possibility of a new virus pandemic cannot be ruled out.We believe that the results of this research will be useful not only for the current COVID-19, but also for the selection of therapeutic drug candidates in a shorter period of time when a virus pandemic occurs in the future, and the risk management system for national emergencies. We believe that this is the underlying technology.

 

About FRONTEO's new coronavirus infection countermeasure "COMBAT COVID-19"

At FRONTEO, we are implementing measures against new coronavirus infections using our AI.Information on this matter and future activities will be released on the special website below.
https://lifescience.fronteo.com/covid-19

 

■ Concept Encoderabout URL: https://lifescience.fronteo.com/concept-encoder/

"Concept Encoder (concept encoder)®, Concept Encoder) ”is a natural language analysis AI (artificial intelligence) developed by FRONTEO specializing in the life science field.It was developed in 2018 with the aim of effectively analyzing and utilizing medical data containing a large amount of free-form text data based on evidence. "Concept Encoder" can be co-analyzed with data other than text, and we are conducting research on co-analysis with numerical data such as gene expression information, vitals and various test values ​​accumulated in the life science field.Patent registration number: Patent No. 6346367

 

■ FRONTEOabout URL: https://www.fronteo.com/

FRONTEO Inc. has developed its own natural language analysis AI (artificial intelligence) engine "KIBIT".®(Kibit) ”and“ concept encoder®(Concept encoder) ”is a company that supports information analysis.Established in August 2003 as a company that supports e-discovery (electronic discovery), which preserves evidence, investigates and analyzes electronic data necessary for international proceedings, and digital forensic investigations, and technologies such as an in-house developed data analysis platform To date, we have supported about 8 international proceedings.In addition, we are applying the unique AI-related technology cultivated in the legal business to areas such as life science and business intelligence, and have achieved results in drug discovery research support, diagnostic support, and work style reform. Listed on TSE Mothers on June 1, 2007.The capital is 6 thousand yen (as of March 26, 2,559,206).

 

[Contact from the press]

Public Relations Officer, FRONTEO Inc. Segawa

TEL: 03-5463-6380 FAX: 03-5463-6345 Email: pr_contact@fronteo.com

[Inquiries about Life Science AI Business]

Life Science AI Business Department, FRONTEO, Inc.

TEL 03-5463-6330 FAX 03-5463-7578 Email: fhc_contact@fronteo.com